The reprogrammed cells originally taken from
schizophrenia patients showed the same transcriptional signatures (or underlying biology) as cells taken from postmortem patients, indicating that the stem cell - derived brain cells successfully recapitulated the disease and identifying possible biological variants that contribute to its onset.
Chronic
schizophrenia patients showed a significant drop in activation of these regions, «thus it appears that they fail to engage these frontal regions,» said Belger.
Not exact matches
In a previous study, the researchers
showed that a group of self - described voice - hearing psychics had similar voice - hearing experiences as
patients with
schizophrenia.
Already this has
shown that
schizophrenia patients have particular problems noticing what has changed in a previously learned scene in which an object has been moved, but do better at recognising when the object has been replaced with something else.
Antipsychotics were originally developed for use in
patients with
schizophrenia or psychosis, but the study
shows that «off - label» prescribing of these drugs to treat the behavioural and psychological symptoms of dementia is a common practice in care homes.
Recently, however, discoveries such as receptor transport abnormalities in the brains of
schizophrenia patients, have started to
show the receptors» deep involvement in neuropsychiatric disorders.
It has been
shown that the number of spindles increases following a day stuffed with learning and declines in the elderly, and in
patients with
schizophrenia.
Previous studies on post-mortem brains and blood samples from
patients with
schizophrenia indicated that their brains
show differences in terms of vascularization.
«This is the first demonstration of the profile of angiogenic molecules expression using neural stem cells derived from
patients with
schizophrenia, which
shows they have a less angiogenic profile when compared to controls,» says Palma.
Patients with
schizophrenia, bipolar disorder and their unaffected relatives
show white matter density and integrity reductions in the anterior limb of the internal capsule (ALIC).
Depressed
patients showed an increased release of the hormone, while
patients with
schizophrenia showed a decreased response.
Both trials enrolled
patients who met the DSM - III / IV criteria for
schizophrenia, and Fanapt ™ was
shown to be superior to placebo in controlling symptoms of
schizophrenia across doses of 12 mg to 24 mg per day.
But research increasingly
shows that when the «white matter» that ties the gray stuff together is damaged or deficient — as it can be in
patients with brain trauma, autism and
schizophrenia — goal - directed task performance can be very poor.